Publicaciones en colaboración con investigadores/as de Hospital General Universitario de Elche (20)

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

2022

  1. Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

    Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210

  2. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

    ESMO open, Vol. 6, Núm. 2, pp. 100062

2015

  1. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer

    Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541

2014

  1. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 865-878

2011

  1. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

    Critical Reviews in Oncology/Hematology, Vol. 77, Núm. 1, pp. 78-84

2010

  1. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers

    Breast Cancer Research and Treatment, Vol. 119, Núm. 1, pp. 221-232

2009

  1. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study

    Annals of Oncology, Vol. 20, Núm. 2, pp. 251-257

  2. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

    Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736

2005

  1. Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer

    Clinical Colorectal Cancer, Vol. 4, Núm. 6, pp. 384-389

2004

  1. Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors

    Anti-Cancer Drugs, Vol. 15, Núm. 5, pp. 469-471

2003

  1. High-dose DICEP chemotherapy versus observation in metastatic breast cancer patients with monotopic disease responding to induction chemotherapy with paclitaxel plus epirubicin. Final results of a phase III GEICAM trial

    Clinical and Translational Oncology, Vol. 5, Núm. 3, pp. 148-155

2002

  1. Oxaliplatin: Results in colorectal carcinoma

    Critical Reviews in Oncology/Hematology, Vol. 44, Núm. 1, pp. 29-44

2001

  1. Tegafur and uracil plus leucovorin in advanced colorectal cancer: a phase II trial

    Clinical colorectal cancer, Vol. 1, Núm. 1, pp. 43-46

2000

  1. Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 2, Núm. 3, pp. 154-158

1999

  1. UFT Plus or Minus Calcium Folinate for Metastatic Golorectal Cancer in Older Patients

    ONCOLOGY, Vol. 13, Núm. 7 SUPPL., pp. 35-40

1998

  1. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study

    Annals of Oncology, Vol. 9, Núm. 7, pp. 727-731

1996

  1. Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial

    Annals of Oncology, Vol. 7, Núm. 6, pp. 581-585

1995

  1. A phase II trial of weekly high dose continuous infusion 5‐fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

    Cancer, Vol. 76, Núm. 4, pp. 559-563